These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 23712330

  • 1. Polymorphisms in ERCC1 C8092A predict progression-free survival in metastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy.
    Chen C, Wang F, Wang Z, Li C, Luo H, Liang Y, An X, Shao J, Li Y.
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):315-22. PubMed ID: 23712330
    [Abstract] [Full Text] [Related]

  • 2. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
    Ryu JS, Hong YC, Han HS, Lee JE, Kim S, Park YM, Kim YC, Hwang TS.
    Lung Cancer; 2004 Jun; 44(3):311-6. PubMed ID: 15140544
    [Abstract] [Full Text] [Related]

  • 3. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
    Quintela-Fandino M, Hitt R, Medina PP, Gamarra S, Manso L, Cortes-Funes H, Sanchez-Cespedes M.
    J Clin Oncol; 2006 Sep 10; 24(26):4333-9. PubMed ID: 16896002
    [Abstract] [Full Text] [Related]

  • 4. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
    Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, Georgoulias V, Mavroudis D.
    Clin Lung Cancer; 2009 Mar 10; 10(2):118-23. PubMed ID: 19362955
    [Abstract] [Full Text] [Related]

  • 5. [Association between polymorphisms of ERCC1 and response in patients with advanced non-small cell lung cancer receiving cisplatin-based chemotherapy].
    Wang J, Zhang Q, Zhang H, Wang Q, Yang X, Gu Y, Zhang S.
    Zhongguo Fei Ai Za Zhi; 2010 Apr 10; 13(4):337-41. PubMed ID: 20677561
    [Abstract] [Full Text] [Related]

  • 6. ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy.
    Rumiato E, Cavallin F, Boldrin E, Cagol M, Alfieri R, Basso D, Castoro C, Ancona E, Amadori A, Ruol A, Saggioro D.
    Pharmacogenet Genomics; 2013 Nov 10; 23(11):597-604. PubMed ID: 23962907
    [Abstract] [Full Text] [Related]

  • 7. Genetic polymorphisms of ERCC1 and their effects on the efficacy of cisplatin-based chemotherapy in advanced esophageal carcinoma.
    Wang Y, Chen J, Li X, He Y, Hu B, Ji C, Xu J.
    Oncol Rep; 2011 Apr 10; 25(4):1047-52. PubMed ID: 21286668
    [Abstract] [Full Text] [Related]

  • 8. ERCC1 Cys8092Ala and XRCC1 Arg399Gln polymorphisms predict progression-free survival after curative radiotherapy for nasopharyngeal carcinoma.
    Jin H, Xie X, Wang H, Hu J, Liu F, Liu Z, Zhou J, Zhang Y, Xi X, Hu B, Liao Y, Tang J.
    PLoS One; 2014 Apr 10; 9(7):e101256. PubMed ID: 25025378
    [Abstract] [Full Text] [Related]

  • 9. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.
    Liang J, Jiang T, Yao RY, Liu ZM, Lv HY, Qi WW.
    Cancer Chemother Pharmacol; 2010 Aug 10; 66(3):493-500. PubMed ID: 19960344
    [Abstract] [Full Text] [Related]

  • 10. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Li F, Sun X, Sun N, Qin S, Cheng H, Feng J, Chen B, Cheng L, Lu Z, Ji J, Zhou Y.
    Am J Clin Oncol; 2010 Oct 10; 33(5):489-94. PubMed ID: 20351547
    [Abstract] [Full Text] [Related]

  • 11. Disease-free survival of patients after surgical resection of non-small cell lung carcinoma and correlation with excision repair cross-complementation group 1 expression and genotype.
    Tseden-Ish M, Choi YD, Cho HJ, Ban HJ, Oh IJ, Kim KS, Song SY, Na KJ, Ahn SJ, Choi S, Kim YC.
    Respirology; 2012 Jan 10; 17(1):127-33. PubMed ID: 21899657
    [Abstract] [Full Text] [Related]

  • 12. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, Lynch TJ, Su L, Christiani DC.
    Clin Cancer Res; 2004 Aug 01; 10(15):4939-43. PubMed ID: 15297394
    [Abstract] [Full Text] [Related]

  • 13. Impact of ERCC1 gene polymorphisms on response to cisplatin based therapy in oral squamous cell carcinoma (OSCC) patients.
    Avinash Tejasvi ML, Maragathavalli G, Putcha UK, Ramakrishna M, Vijayaraghavan R, Anulekha Avinash CK.
    Indian J Pathol Microbiol; 2020 Aug 01; 63(4):538-543. PubMed ID: 33154302
    [Abstract] [Full Text] [Related]

  • 14. Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy.
    Sodja E, Knez L, Kern I, Ovčariček T, Sadikov A, Cufer T.
    Eur J Cancer; 2012 Dec 01; 48(18):3378-85. PubMed ID: 22795264
    [Abstract] [Full Text] [Related]

  • 15. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients.
    Takenaka T, Yano T, Kiyohara C, Miura N, Kouso H, Ohba T, Kometani T, Shoji F, Yoshino I, Maehara Y.
    Lung Cancer; 2010 Jan 01; 67(1):101-7. PubMed ID: 19361884
    [Abstract] [Full Text] [Related]

  • 16. Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma.
    Hui EP, Ma BB, Chan KC, Chan CM, Wong CS, To KF, Chan AW, Tung SY, Ng WT, Cheng AC, Lee VH, Chan SL, Loong HH, Kam MK, Leung SF, Ho R, Mo F, Ngan RK, Chan AT.
    Cancer; 2015 Aug 15; 121(16):2720-9. PubMed ID: 25946469
    [Abstract] [Full Text] [Related]

  • 17. ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy.
    Kamikozuru H, Kuramochi H, Hayashi K, Nakajima G, Yamamoto M.
    Int J Oncol; 2008 May 15; 32(5):1091-6. PubMed ID: 18425336
    [Abstract] [Full Text] [Related]

  • 18. Multicenter phase II study of capecitabine combined with nedaplatin for recurrent and metastatic nasopharyngeal carcinoma patients after failure of cisplatin-based chemotherapy.
    Peng PJ, Ou XQ, Chen ZB, Liao H, Peng YL, Wang SY, Zhang HY, Lin Z.
    Cancer Chemother Pharmacol; 2013 Aug 15; 72(2):323-8. PubMed ID: 23728706
    [Abstract] [Full Text] [Related]

  • 19. Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer.
    Krivak TC, Darcy KM, Tian C, Armstrong D, Baysal BE, Gallion H, Ambrosone CB, DeLoia JA, Gynecologic Oncology Group Phase III Trial.
    J Clin Oncol; 2008 Jul 20; 26(21):3598-606. PubMed ID: 18640939
    [Abstract] [Full Text] [Related]

  • 20. Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy.
    Huang PY, Li Y, Mai HQ, Luo RZ, Cai YC, Zhang L.
    Oral Oncol; 2012 Oct 20; 48(10):964-968. PubMed ID: 22571922
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.